Tolcapone, COMT Polymorphisms and Pharmacogenomic Treatment of Schizophrenia

• Kozikowski AP , RothB, TropshaA: Why academic drug discovery makes sense.Science313(5791) , 1235–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Roth BL : Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?Dialogues Clin. Neurosci.8(3) , 303–309 (2006).
   PubMedGoogle Scholar
• Remington G , FoussiasG, AgidO: Progress in defining optimal treatment outcome in schizophrenia.CNS Drugs24(1) , 9–20 (2010).
   PubMed Web of Science ®Google Scholar
• Mojtabai R , FochtmannL, ChangSW, KotovR, CraigTJ, BrometE: Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.Schizophr. Bull.35(4) , 679–695 (2009).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B , FentonWS, CarpenterWT, MarderSR: The NIMH-MATRICS consensus statement on negative symptoms.Schizophr. Bull.32(2) , 214–219 (2006).
   PubMed Web of Science ®Google Scholar
• Knapp M , McCroneP, LeeuwenkampO: Associations between negative symptoms, service use patterns and cost in patients with schizophrenia in five European countries.Clin. Neuropsychiatry5(4) , 195–205 (2008).
   Google Scholar
• Arranz MJ , KapurS: Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Schizophr. Bull.34(6) , 1130–1144 (2008).
   PubMed Web of Science ®Google Scholar
• Tandon R , NasrallahHA, KeshavanMS: Schizophrenia, ‘just the facts‘ 5. Treatment and prevention. Past, present, and future.Schizophr. Res.122(1–3) , 1–23 (2010).
   PubMed Web of Science ®Google Scholar
• Gray JA , RothBL: The pipeline and future of drug development in schizophrenia.Mol. Psychiatry12(10) , 904–922 (2007).
   PubMed Web of Science ®Google Scholar
• Huotari M , GogosJA, KarayiorouM et al.: Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.Eur. J. Neurosci.15(2) , 246–256 (2002).
   PubMed Web of Science ®Google Scholar
• Gogos JA , MorganM, LuineV, OgawaS, PfaffD, KarayiourgouM: Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour.Proc. Natl Acad. Sci. USA95(17) , 9991–9996 (1998).
   PubMed Web of Science ®Google Scholar
• Tunbridge EM , BannermanDM, SharpT, HarrisonPJ: Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.J. Neurosci.24(23) , 5331–5335 (2004).
   PubMed Web of Science ®Google Scholar
• Tunbridge EM , HarrisonPJ, WeinbergerDR: Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond.Biol. Psychiatry60(2) , 141–151 (2006).
   PubMed Web of Science ®Google Scholar
• Boudíková B , SzumlanskiC, MaidakB, WeinshilboumR: Human liver catechol-O-methyltransferase pharmacogenetics.Clin. Pharmacol. Ther.48(4) , 381–389 (1990).
   PubMed Web of Science ®Google Scholar
• Chen J , LipskaBK, HalimN et al.: Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.Am. J. Hum. Genet.75(5) , 807–821 (2004).
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM , OtternessDM, SzumlanskiCL: Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase.Annu. Rev. Pharmacol. Toxicol.39 , 19–52 (1999).
   PubMed Web of Science ®Google Scholar
• Nackley AG , ShabalinaSA, TchivilevaIE et al.: Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.Science314(5807) , 1930–1933 (2006).
   PubMed Web of Science ®Google Scholar
• Bray NJ , BucklandPR, WilliamsNM et al.: A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain.Am. J. Hum. Genet.73(1) , 152–161 (2003).
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS , MulyEC III, Williams GV: D1 receptors in prefrontal cells and circuits. Brain Res. Rev.31(2–3) , 295–301 (2000).
   PubMed Web of Science ®Google Scholar
• Matsumoto M , WeickertCS, AkilM et al.: Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function.Neuroscience116(1) , 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• de Frias CM , AnnerbrinkK, WestbergL, ErikssonE, AdolfssonR, NilssonLG: COMT gene polymorphism is associated with declarative memory in adulthood and old age.Behav. Genet.34(5) , 533–539 (2004).
   PubMed Web of Science ®Google Scholar
• Bertolino A , RubinoV, SambataroF et al.: Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype.Biol. Psychiatry60(11) , 1250–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Mattay VS , GoldbergTE, FeraF et al.: Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. USA100(10) , 6186–6191 (2003).
   PubMed Web of Science ®Google Scholar
• Swerdlow NR , GeyerMA, BraffDL: Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges.Psychopharmacology156(2–3) , 194–215 (2001).
   PubMed Web of Science ®Google Scholar
• Braff DL , LightGA: The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia.Dialogues Clin. Neurosci.7(2) , 125–135 (2005).
   PubMedGoogle Scholar
• Bitsios P , GiakoumakiSG, TheouK, FrangouS: Increased PPI is associated with better strategy formation and execution times in healthy males.Neuropsychologia44(12) , 2494–2499 (2006).
   PubMed Web of Science ®Google Scholar
• Giakoumaki SG , BitsiosP, FrangouS: The level of PPI in healthy individuals may index cortical modulation of early information processing.Brain Res.1078(1) , 168–170 (2006).
   PubMedGoogle Scholar
• Bitsios P , GiakoumakiSG, FrangouS: The effects of dopamine agonists on prepulse inhibition (PPI) in healthy males depend on baseline PPI values.Psychopharmacology182(1) , 144–152 (2005).
   PubMed Web of Science ®Google Scholar
• Roussos P , GiakoumakiSG, RogdakiM, PavlakisS, FrangouS, BitsiosP: Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism.Psychol Med38(11) , 1651–1658 (2008).
   PubMed Web of Science ®Google Scholar
• Giakoumaki SG , RoussosP, BitsiosP: Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.Neuropsychopharmacology33(13) , 3058–3068 (2008).
   PubMed Web of Science ®Google Scholar
• Quednow BB , WagnerM, MössnerR, MaierW, KühnKU: Sensorimotor gating of schizophrenia patients depends on catechol O-methyltransferase Val158Met polymorphism.Schizophr. Bull.36(2) , 341–346 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A , KohnPD, KolachanaB et al.: Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.Nat. Neurosci.8(5) , 594–596 (2005).
   PubMed Web of Science ®Google Scholar
• Akil M , KolachanaBS, RothmondDA, HydeTM, WeinbergerDR, KleinmanJE: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain.J. Neurosci.23(6) , 2008–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A , GilR, KrystalJ et al.: Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.Am. J. Psychiatry155(6) , 761–767 (1998).
   PubMed Web of Science ®Google Scholar
• Laruelle M , Abi-DarghamA, GilR, KegelesL, InnisR: Increased dopamine transmission in schizophrenia: relationship to illness phases.Biol. Psychiatry46(1) , 56–72 (1999).
   PubMed Web of Science ®Google Scholar
• Grace AA : Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia.J. Neural Transm. Gen. Sect.91(2–3) , 111–134 (1993).
   PubMed Web of Science ®Google Scholar
• Bilder RM , VolavkaJ, LachmanHM, GraceAA: The catechol-O-methyltransferase polymorphism: relations to the tonic–phasic dopamine hypothesis and neuropsychiatric phenotypes.Neuropsychopharmacology29(11) , 1943–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Weinberger DR , BermanKF, DanielDG: Mesoprefrontal cortical dopaminergic activity and prefrontal hypofunction in schizophrenia.Clin. Neuropharmacol.15(Suppl. 1, Pt A) , 568A–569A (1992).
   PubMedGoogle Scholar
• Callicott JH , EganMF, MattayVS et al.: Abnormal fMRI response of the dorsolateral prefrontal cortex in intact siblings of patients with schizophrenia [published erratum appears in Am. J. Psychiatry 161(6), 1145 (2004)].Am. J. Psychiatry160(4) , 709–719 (2003).
   PubMed Web of Science ®Google Scholar
• Cannon TD , RossoIM, HollisterJM, BeardenCE, SanchezLE, HadleyT: A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia.Schizophr. Bull.26(2) , 351–366 (2000).
   PubMed Web of Science ®Google Scholar
• Shprintzen RJ , HigginsAM, AntshelK, FremontW, RoizenN, KatesW: Velo-cardio-facial syndrome.Curr. Opin. Pediatr.17(6) , 725–730 (2005).
   PubMed Web of Science ®Google Scholar
• Owen MJ , WilliamsHJ, O‘DonovanMC: Schizophrenia genetics: advancing on two fronts.Curr. Opin. Genet. Dev.19(3) , 266–270 (2009).
   PubMed Web of Science ®Google Scholar
• Williams HJ , OwenMJ, O‘DonovanMC: Is COMT a susceptibility gene for schizophrenia?Schizophr. Bull.33(3) , 635–641 (2007).
   PubMed Web of Science ®Google Scholar
• Zurcher G , DingemanseJ, Da Prada M: Ro-40-7592, a Potent Inhibitor of Extracerebral and Brain Catechol-O-Methyltransferase: Preclinical and Clinical Findings. In: New Development in Therapy of Parkinson‘s Disease. Agnoli A, Campanella G (Eds). John Libbey SRL, Rome, Italy, 37–43 (1991).
   Google Scholar
• Ceravolo R , PicciniP, BaileyDL, JorgaKM, BrysonH, BrooksDJ: 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson‘s disease.Synapse43(3) , 201–207 (2002).
   PubMed Web of Science ®Google Scholar
• Forsberg M , LehtonenM, HeikkinenM, SavolainenJ, JärvinenT, MännistöPT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.J. Pharmacol. Exp. Ther.304(2) , 498–506 (2003).
   PubMed Web of Science ®Google Scholar
• Jorga KM : Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.Neurology50(5 Suppl. 5) , S31–S38 (1998).
   PubMedGoogle Scholar
• Apud JA , WeinbergerDR: Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.CNS Drugs21(7) , 535–557 (2007).
   PubMed Web of Science ®Google Scholar
• Olanow CW , WatkinsPB: Tolcapone: an efficacy and safety review.Clin. Neuropharmacol.30(5) , 287–294 (2007).
   PubMed Web of Science ®Google Scholar
• Olanow CW : Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.Arch. Neurol.57 , 263–267 (2000).
   PubMed Web of Science ®Google Scholar
• Apud JA , MattayV, ChenJ et al.: Tolcapone improves cognition and cortical information processing in normal human subjects.Neuropsychopharmacology32(5) , 1011–1020 (2007).
   PubMed Web of Science ®Google Scholar
• Roussos P , GiakoumakiSG, BitsiosP: Tolcapone effects on gating, working memory and mood interact with the synonymous COMT rs4818C/G polymorphism.Biol. Psychiatry66(11) , 997–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Smolka MN , SchumannG, WraseJ et al.: Catechol-O-methyltransferase Val158Met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J. Neurosci.25(4) , 836–842 (2005).
   PubMed Web of Science ®Google Scholar
• Drabant EM , HaririAR, Meyer-LindenbergA et al.: Catechol O-methyltransferase Val158Met genotype and neural mechanisms related to affective arousal and regulation.Arch. Gen. Psychiatry63(12) , 1396–1406 (2006).
   PubMed Web of Science ®Google Scholar
• Weiss EM , StadelmannE, KohlerCG et al.: Differential effect of catechol-O-methyltransferase Val158Met genotype on emotional recognition abilities in healthy men and women.J. Int. Neuropsychol. Soc.13(5) , 881–887 (2007).
   PubMed Web of Science ®Google Scholar
• Roussos P , GiakoumakiSG, PavlakisS, BitsiosP: Planning, decision-making and the COMT rs4818 polymorphism in healthy males.Neuropsychologia46(2) , 757–763 (2008).
   PubMed Web of Science ®Google Scholar
• Giakoumaki S , TsapakisEM, RoussosP, ChrysoulakiA, KopsahiliI, BitsiosP: Single dose tolcapone administration improves working memory and sensorimotor gating in psychotic patients.Schizophr. Res.117(2–3) , 266 (2010).
   Web of Science ®Google Scholar
• Harrison PJ , TunbridgeEM: Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders.Neuropsychopharmacology33(13) , 3037–3045 (2008).
   PubMed Web of Science ®Google Scholar
• Tunbridge EM , WeickertCS, KleinmanJE et al.: Catechol-O-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan.Cereb. Cortex17(5) , 1206–1212 (2007).
   PubMed Web of Science ®Google Scholar
• Strous RD , RitsnerNS, AdlerS et al.: Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia.Eur. Neuropsychopharmacol.19(1) , 14–22 (2009).
   PubMed Web of Science ®Google Scholar
• Insel TR : Translating scientific opportunity into public health impact: a strategic plan for research on mental illness.Arch. Gen. Psychiatry66(2) , 128–133 (2009).
   PubMed Web of Science ®Google Scholar
• McGorry PD , NelsonB, AmmingerP et al.: Intervention in individuals at ultra high risk for psychosis: a review and future directions.J. Clin. Psychiatry70(9) , 1206–1212 (2009).
   PubMed Web of Science ®Google Scholar

▪ Website

• National Institutes of Health Clinical Center (CC) www.clinicaltrials.gov/ct2/show/NCT00044083
   Google Scholar